Raj Sean D, Fein-Zachary Valerie, Slanetz Priscilla J
Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Semin Ultrasound CT MR. 2018 Feb;39(1):16-24. doi: 10.1053/j.sult.2017.08.001. Epub 2017 Aug 14.
Although dense breast tissue is a normal and routine finding on screening mammography, dense breast tissue is associated with an independent increased risk for breast cancer. It is well known that screening mammography has a decreased sensitivity for cancer detection in women with dense breasts. Over the past decade, there has been increased interest generated among patients, physicians, and legislators regarding how best to screen dense-breasted women culminating in 2009 with the passage of a breast density notification law in Connecticut. Since that time, over half the United States has passed similar notification laws. Despite this, controversy remains as to the optimal supplemental screening modality to complement mammography as each imaging modality (digital breast tomosynthesis, whole breast ultrasound, magnetic resonance imaging, contrast-enhanced mammography, and molecular breast imaging) has variable benefits and limitations.
尽管致密乳腺组织在乳腺筛查钼靶检查中是一种正常且常见的表现,但致密乳腺组织与乳腺癌独立风险增加相关。众所周知,乳腺筛查钼靶对致密型乳腺女性的癌症检测敏感性降低。在过去十年中,患者、医生和立法者对如何最好地筛查致密型乳腺女性的兴趣不断增加,最终在2009年康涅狄格州通过了一项乳腺密度通知法。自那时以来,美国超过一半的州通过了类似的通知法。尽管如此,关于补充乳腺钼靶检查的最佳筛查方式仍存在争议,因为每种成像方式(数字乳腺断层合成、全乳超声、磁共振成像、对比增强乳腺钼靶和分子乳腺成像)都有不同的益处和局限性。